NASDAQ:OSUR - OraSure Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.77 -0.79 (-6.83 %) (As of 03/22/2019 04:00 PM ET)Previous Close$11.56Today's Range$10.77 - $11.5552-Week Range$9.15 - $18.45Volume436,503 shsAverage Volume630,590 shsMarket Capitalization$664.11 millionP/E Ratio21.54Dividend YieldN/ABeta1.27 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania. Receive OSUR News and Ratings via Email Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:OSUR Previous Symbol CUSIP68554V10 CIK1116463 Webwww.orasure.com Phone610-882-1820Debt Debt-to-Equity RatioN/A Current Ratio7.84 Quick Ratio7.02Price-To-Earnings Trailing P/E Ratio21.54 Forward P/E Ratio35.90 P/E Growth3.05 Sales & Book Value Annual Sales$181.74 million Price / Sales3.65 Cash Flow$0.5762 per share Price / Cash Flow18.69 Book Value$4.62 per share Price / Book2.33Profitability EPS (Most Recent Fiscal Year)$0.50 Net Income$20.40 million Net Margins11.22% Return on Equity8.45% Return on Assets7.64%Miscellaneous Employees398 Outstanding Shares61,663,000Market Cap$664.11 million Next Earnings Date5/1/2019 (Estimated) OptionableOptionable OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions What is OraSure Technologies' stock symbol? OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR." How were OraSure Technologies' earnings last quarter? OraSure Technologies, Inc. (NASDAQ:OSUR) posted its quarterly earnings data on Wednesday, February, 6th. The medical instruments supplier reported $0.20 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.11 by $0.09. The medical instruments supplier earned $50.25 million during the quarter, compared to analyst estimates of $47.77 million. OraSure Technologies had a net margin of 11.22% and a return on equity of 8.45%. The business's revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.12 EPS. View OraSure Technologies' Earnings History. When is OraSure Technologies' next earnings date? OraSure Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for OraSure Technologies. What guidance has OraSure Technologies issued on next quarter's earnings? OraSure Technologies issued an update on its first quarter earnings guidance on Wednesday, February, 6th. The company provided EPS guidance of $(0.07)-(0.06) for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.09. The company issued revenue guidance of $29.0-30.5 million, compared to the consensus revenue estimate of $44.35 million.OraSure Technologies also updated its Q1 2019 guidance to $-0.07--0.06 EPS. What price target have analysts set for OSUR? 2 brokers have issued twelve-month price objectives for OraSure Technologies' shares. Their forecasts range from $16.00 to $16.00. On average, they expect OraSure Technologies' stock price to reach $16.00 in the next year. This suggests a possible upside of 48.6% from the stock's current price. View Analyst Price Targets for OraSure Technologies. What is the consensus analysts' recommendation for OraSure Technologies? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OraSure Technologies. What are Wall Street analysts saying about OraSure Technologies stock? Here are some recent quotes from research analysts about OraSure Technologies stock: 1. Canaccord Genuity analysts commented, "We reiterate our BUY, trim PT to $16. Q1/19 guide disappoints. OSUR initiated a Q1/19 revenue guide of $29-30.5M, or 33% below the Street at the midpoint, and EPS of $(0.06)-$(0.07), below our $0.02E/Street’s $0.07, as it expects lower sales from a large DTC customer. While we don’t know the precise details, management indicated to us that its large DTC customer has changed its strategy" and indicated to OSUR it will not need as many kits in Q1/19. What is going on at 23andMe? We know from LabCorp that something is going on" at 23andMe that is having a ripple effect, and we suspect that 23andMe is possibly (1) upgrading its technology to enable greater health insights to patients; and (2) reducing its test discounting or its heavy TV ad spend, at least in 1H/19 vs. prior years." (2/7/2019) 2. According to Zacks Investment Research, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. " (11/7/2018) Has OraSure Technologies been receiving favorable news coverage? Headlines about OSUR stock have trended positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OraSure Technologies earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. Who are some of OraSure Technologies' key competitors? Some companies that are related to OraSure Technologies include Cantel Medical (CMD), Irhythm Technologies (IRTC), Nevro (NVRO), Atrion (ATRI), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), K2M Group (KTWO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS) and AngioDynamics (ANGO). What other stocks do shareholders of OraSure Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include XOMA (XOMA), Citigroup (C), Merit Medical Systems (MMSI), Energy Transfer LP Unit (ET), Alnylam Pharmaceuticals (ALNY), Ford Motor (F), Sarepta Therapeutics (SRPT), Opko Health (OPK), Walt Disney (DIS) and Celldex Therapeutics (CLDX). Who are OraSure Technologies' key executives? OraSure Technologies' management team includes the folowing people: Dr. Stephen S. Tang, Pres, CEO & Director (Age 58)Mr. Brian L. Smith, Vice Chairman & EVP of Innovation (Age 60)Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 60)Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 65)Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 51) Who are OraSure Technologies' major shareholders? OraSure Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.53%), Dimensional Fund Advisors LP (4.76%), Dimensional Fund Advisors LP (4.76%), American Capital Management Inc. (2.81%), Peregrine Capital Management LLC (1.74%) and Penn Capital Management Co. Inc. (1.65%). Company insiders that own OraSure Technologies stock include Anthony Zezzo II, Brian Smith, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mara G Aspinall, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies. Which institutional investors are selling OraSure Technologies stock? OSUR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Bank of America Corp DE, BlackRock Inc., Barclays PLC, Brinker Capital Inc. and Citigroup Inc.. View Insider Buying and Selling for OraSure Technologies. Which institutional investors are buying OraSure Technologies stock? OSUR stock was purchased by a variety of institutional investors in the last quarter, including American Capital Management Inc., Norges Bank, Penn Capital Management Co. Inc., Two Sigma Investments LP, Squarepoint Ops LLC, New York State Common Retirement Fund, D. E. Shaw & Co. Inc. and Two Sigma Advisers LP. View Insider Buying and Selling for OraSure Technologies. How do I buy shares of OraSure Technologies? Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OraSure Technologies' stock price today? One share of OSUR stock can currently be purchased for approximately $10.77. How big of a company is OraSure Technologies? OraSure Technologies has a market capitalization of $664.11 million and generates $181.74 million in revenue each year. The medical instruments supplier earns $20.40 million in net income (profit) each year or $0.50 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe. What is OraSure Technologies' official website? The official website for OraSure Technologies is http://www.orasure.com. How can I contact OraSure Technologies? OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected] MarketBeat Community Rating for OraSure Technologies (NASDAQ OSUR)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 448 (Vote Outperform)Underperform Votes: 307 (Vote Underperform)Total Votes: 755MarketBeat's community ratings are surveys of what our community members think about OraSure Technologies and other stocks. Vote "Outperform" if you believe OSUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSUR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: How is a buy-side analyst different from a sell-side analyst?